Exact Sciences Corp. is an American molecular diagnostics company that is headquartered in Madison, Wisconsin. The company was founded in 1995 as Exact Laboratories and was initially focused on developing non-invasive screening tests for colon cancer. The company changed its name to Exact Sciences Corp. in 2009 and has since expanded its portfolio to include diagnostic tests for a range of cancers and other diseases.
Exact Sciences Corp. has developed a non-invasive colorectal cancer screening test called Cologuard, which uses a stool sample to detect the presence of cancer or pre-cancerous growths in the colon. The company has also developed other diagnostic tests for cancers such as lung, pancreatic, and liver cancer. In addition to cancer diagnostics, Exact Sciences has partnered with pharmaceutical companies to develop diagnostic tests for other diseases, such as rheumatoid arthritis.
In addition to its diagnostic products, Exact Sciences has made strategic acquisitions to expand its offerings. In 2018, the company acquired Genomic Health, a company focused on developing genomic-based diagnostic tests for cancer. The acquisition of Genomic Health expanded Exact Sciences' portfolio to include tests that can help determine a patient's risk of developing certain types of cancer and can help guide treatment decisions.
Exact Sciences has also been investing in research and development to expand its product offerings. The company has a robust pipeline of diagnostic tests in various stages of development, including tests for bladder cancer and pre-cancerous growths in the colon.
The company's growth and success have been recognized through various industry accolades. In 2020, Exact Sciences was named to the Fortune 500 list for the first time, and the company was also recognized as one of the World's Most Innovative Companies by Fast Company in 2021.